Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. The company granted stock options for 60,000 shares to one new non-executive employee at $1.06 per share, and restricted stock units (RSUs) for 60,800 shares to two new non-executive employees.

The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a four-year vesting schedule. The stock options vest 25% after one year, with remaining 75% vesting monthly over 36 months, while RSUs vest 25% annually over four years.

News Market Reaction – FATE

-3.70%

4 alerts

-3.70% News Effect

-$5M Valuation Impact

$130M Market Cap

0.3x Rel. Volume

On the day this news was published, FATE declined 3.70%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $130M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on August 4, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 60,000 shares of the Company’s common stock at an exercise price per share of $1.06, which was the closing price per share of the Company’s common stock as reported by NASDAQ on August 4, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 60,800 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

FAQ

What stock options did Fate Therapeutics (FATE) grant to new employees in August 2025?

Fate Therapeutics granted stock options for 60,000 shares at $1.06 per share to one non-executive employee, with a four-year vesting schedule.

How many RSUs did Fate Therapeutics award in August 2025?

Fate Therapeutics awarded RSUs representing 60,800 shares to two newly-hired non-executive employees.

What is the vesting schedule for Fate Therapeutics' August 2025 stock options?

The stock options vest over four years, with 25% vesting after one year and the remaining 75% vesting in monthly installments over 36 months.

What is Fate Therapeutics' main business focus?

Fate Therapeutics is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.